Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
Articolo
Data di Pubblicazione:
2022
Citazione:
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments / C.A. Maronese, M.A. Pimentel, M.M. Li, G. Genovese, A.G. Ortega-Loayza, A.V. Marzano. - In: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. - ISSN 1175-0561. - 23:5(2022 May 24), pp. 615-634. [10.1007/s40257-022-00699-8]
Abstract:
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target. T helper 17/T helper 1-skewed inflammation and exaggerated inflammasome activation lead to a dysregulated neutrophil-dominant milieu with high levels of tumor necrosis factor-α, interleukin (IL)-1β, IL-1α, IL-8, IL-12, IL-15, IL-17, IL-23, and IL-36. Low-evidence studies and a lack of validated diagnostic and response criteria have hindered the discovery and validation of new effective treatments for pyoderma gangrenosum. We review established and emerging treatments for pyoderma gangrenosum. A therapeutic algorithm based on available evidence is also provided. For emerging treatments, we review target molecules and their role in the pathogenesis of pyoderma gangrenosum.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
C.A. Maronese, M.A. Pimentel, M.M. Li, G. Genovese, A.G. Ortega-Loayza, A.V. Marzano
Link alla scheda completa: